Opinion Brendan Shaw is principal at Shawview Consulting, a specialised consulting and advisory firm for public and private sector leaders in the areas of government-business relations, policy and strategic change, with a focus on the health and pharmaceutical sectors. He is also Adjunct Senior Lecturer in Pharmaceutical Medicine, School of Medical Sciences…

Opinion Despite the disproportionately high numbers of females in the healthcare and life-sciences industries, and the fact that women are the main decision makers when it comes to family health, there is still inequality in pay and career progression. Carla Smith gives us the stats and explains why equality in the…

Opinion Robin Toft is the Author of WE CAN™, the Executive Woman’s Guide to Career Advancement and founder and CEO of Toft Group Executive Search, where she combines a deep inside knowledge of the life science industry with a passion for building game-changing management teams. In this article, she discusses the…

Diversity For international women’s day 2019, PharmaBoardroom looks back on conversations we have had with inspiring female pharma leaders to bring you their words of wisdom on the value of diversity, tackling gender inequalities and closing the gap.   Big Pharma & Gender Equality Cristina Campos, vice-president at APIFARMA A key player…

Spain Having largely recovered from the impact of the global financial crisis and with several impressive fundamentals in place, Spain once again stands as one of Europe’s premier healthcare and life science investment destinations.   These fundamentals include a revamped market access process that puts the Iberian nation on a par…

Egypt On Tuesday, February 12th, Pharmaboardroom attended a breakfast event hosted by the British Egyptian Business Association (BEBA) on competition law at the Cairo Semiramis Intercontinental Hotel. The theme for the event was competition law and its application in the Egyptian market, with the topic being introduced through a speech by…

Algeria Yacine Sellam, president of the Algerian Society for Regulatory Affairs & Pharmacoeconomics, outlines the progress made under Algeria’s National Cancer Plan and the steps that still need to be taken to ensure all Algerian cancer patients can receive the care they need.   It is undeniable that tangible progress has…

Rare Diseases Long regarded as a neglected backwater within the drug discovery landscape and the preserve of only a handful of niche players, the rare disease space has been undergoing an extraordinary turnaround in fortunes of late.   According to EvaluatePharma’s forecasts, orphan drug sales are set to grow 11 percent each…

Rare Diseases The 28th February 2019, marks the twelfth international Rare Disease Day. On and around this day hundreds of patient organisations from countries and regions across the globe will strive to raise awareness of some of the world’s rarest disease. For many of the rare diseases out there, we are yet to…

Ipsen Following on from Johnson & Johnson’s acquisition of Actelion in January 2017 and Takeda’s takeover of Shire two years later, pharma multinationals’ rush to snap up rare disease specialists continues with Ipsen’s proposed acquisition of Clementia Pharmaceuticals. Industry insiders predict that this trend is set to continue well into the…

Mexico Cristobal Thompson is the executive director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). In this article, he introduces us to an exciting new youth program set up to improve unemployment rates in Mexico and how the pharmaceutical industry is getting involved.    The investment in human capital is an…

China China’s regulator approved a biosimilar version of Roche’s Rituxan this week, the first such drug ever to be given the green light in the country. With numerous other biological copycats of blockbuster drugs in development, potentially difficult times lie ahead for Roche and other Big Pharma firms in China.  …